Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients with Coronavirus Disease 2019

Evan M. Bloch; Daniele Focosi; Shmuel Shoham; Jonathon Senefeld; Aaron A.R. Tobian; Lindsey R. Baden; Pierre Tiberghien; David J. Sullivan; Claudia Cohn; Veronica Dioverti; Jeffrey P. Henderson; Cynthia So-Osman; Justin E. Juskewitch; Raymund R. Razonable; Massimo Franchini; Ruchika Goel; Brenda J. Grossman; Arturo Casadevall; Michael J. Joyner; Robin K. Avery; Liise Anne Pirofski; Kelly A. Gebo

doi:10.1093/cid/ciad066

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients with Coronavirus Disease 2019

Evan M. Bloch, Daniele Focosi, Shmuel Shoham, Jonathon Senefeld, Aaron A.R. Tobian, Lindsey R. Baden, Pierre Tiberghien, David J. Sullivan, Claudia Cohn, Veronica Dioverti, Jeffrey P. Henderson, Cynthia So-Osman, Justin E. Juskewitch, Raymund R. Razonable, Massimo Franchini, Ruchika Goel, Brenda J. Grossman, Arturo Casadevall, Michael J. Joyner, Robin K. AveryLiise Anne Pirofski, Kelly A. Gebo

Research output: Contribution to journal › Review article › peer-review

Abstract

Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-Titer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective.

Original language	English (US)
Pages (from-to)	2018-2024
Number of pages	7
Journal	Clinical Infectious Diseases
Volume	76
Issue number	11
DOIs	https://doi.org/10.1093/cid/ciad066
State	Published - Jun 1 2023

Keywords

antibodies
immunocompromised host
passive immunization
plasma

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciad066

Cite this

Bloch, E. M., Focosi, D., Shoham, S., Senefeld, J., Tobian, A. A. R., Baden, L. R., Tiberghien, P., Sullivan, D. J., Cohn, C., Dioverti, V., Henderson, J. P., So-Osman, C., Juskewitch, J. E., Razonable, R. R., Franchini, M., Goel, R., Grossman, B. J., Casadevall, A., Joyner, M. J., ... Gebo, K. A. (2023). Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients with Coronavirus Disease 2019. Clinical Infectious Diseases, 76(11), 2018-2024. https://doi.org/10.1093/cid/ciad066

Bloch, EM, Focosi, D, Shoham, S, Senefeld, J, Tobian, AAR, Baden, LR, Tiberghien, P, Sullivan, DJ, Cohn, C, Dioverti, V, Henderson, JP, So-Osman, C, Juskewitch, JE, Razonable, RR, Franchini, M, Goel, R, Grossman, BJ, Casadevall, A, Joyner, MJ, Avery, RK, Pirofski, LA & Gebo, KA 2023, 'Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients with Coronavirus Disease 2019', Clinical Infectious Diseases, vol. 76, no. 11, pp. 2018-2024. https://doi.org/10.1093/cid/ciad066

@article{7e2731a3cf794a7280578fdb361df8c4,

title = "Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients with Coronavirus Disease 2019",

abstract = "Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-Titer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective.",

keywords = "antibodies, immunocompromised host, passive immunization, plasma",

author = "Bloch, {Evan M.} and Daniele Focosi and Shmuel Shoham and Jonathon Senefeld and Tobian, {Aaron A.R.} and Baden, {Lindsey R.} and Pierre Tiberghien and Sullivan, {David J.} and Claudia Cohn and Veronica Dioverti and Henderson, {Jeffrey P.} and Cynthia So-Osman and Juskewitch, {Justin E.} and Razonable, {Raymund R.} and Massimo Franchini and Ruchika Goel and Grossman, {Brenda J.} and Arturo Casadevall and Joyner, {Michael J.} and Avery, {Robin K.} and Pirofski, {Liise Anne} and Gebo, {Kelly A.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2023",

month = jun,

day = "1",

doi = "10.1093/cid/ciad066",

language = "English (US)",

volume = "76",

pages = "2018--2024",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients with Coronavirus Disease 2019

AU - Bloch, Evan M.

AU - Focosi, Daniele

AU - Shoham, Shmuel

AU - Senefeld, Jonathon

AU - Tobian, Aaron A.R.

AU - Baden, Lindsey R.

AU - Tiberghien, Pierre

AU - Sullivan, David J.

AU - Cohn, Claudia

AU - Dioverti, Veronica

AU - Henderson, Jeffrey P.

AU - So-Osman, Cynthia

AU - Juskewitch, Justin E.

AU - Razonable, Raymund R.

AU - Franchini, Massimo

AU - Goel, Ruchika

AU - Grossman, Brenda J.

AU - Casadevall, Arturo

AU - Joyner, Michael J.

AU - Avery, Robin K.

AU - Pirofski, Liise Anne

AU - Gebo, Kelly A.

PY - 2023/6/1

Y1 - 2023/6/1

N2 - Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-Titer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective.

AB - Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) is a safe and effective treatment for COVID-19 in immunocompromised (IC) patients. IC patients have a higher risk of persistent infection, severe disease, and death from COVID-19. Despite the continued clinical use of CCP to treat IC patients, the optimal dose, frequency/schedule, and duration of CCP treatment has yet to be determined, and related best practices guidelines are lacking. A group of individuals with expertise spanning infectious diseases, virology and transfusion medicine was assembled to render an expert opinion statement pertaining to the use of CCP for IC patients. For optimal effect, CCP should be recently and locally collected to match circulating variant. CCP should be considered for the treatment of IC patients with acute and protracted COVID-19; dosage depends on clinical setting (acute vs protracted COVID-19). CCP containing high-Titer severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, retains activity against circulating SARS-CoV-2 variants, which have otherwise rendered monoclonal antibodies ineffective.

KW - antibodies

KW - immunocompromised host

KW - passive immunization

KW - plasma

UR - http://www.scopus.com/inward/record.url?scp=85151721720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151721720&partnerID=8YFLogxK

U2 - 10.1093/cid/ciad066

DO - 10.1093/cid/ciad066

M3 - Review article

C2 - 36740590

AN - SCOPUS:85151721720

SN - 1058-4838

VL - 76

SP - 2018

EP - 2024

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 11

ER -

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients with Coronavirus Disease 2019

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this